Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity
TÜBINGEN, Germany, Jan. 8, 2026, 03:00 GMT-05
Acousia-Therapeutics
Read full article →